performed analysis: A.F.B.; drafted manuscript: A-F.B.; and revised
and approved manuscript: A.F.B., R.M. and M.C.E.

Competing interests. We have no competing interests.

Funding. All authors were supported by NIH grant no. U01CA182915.
The funders had no role in study design, data collection and analysis,
decision to publish or preparation of the manuscript.

References

1. Centers for Disease Control and Prevention. 2017 2013-2014. J. Infect. Dis. 215, 1070-1079. 10. Holford TR. 1983 The estimation of age, period
Genital HPV infection - fact sheet. See https:/www. (doi:10.1093/infdis/jix057) and cohort effects for vital rates. Biometrics 39,
cdc.gov/std/hpv/stdfact-hpv.htm. 6. Brouwer AF, Eisenberg MC, Carey TE, Meza R, 311-324. (doi:10.2307/2531004)

2. Jemal A et al. 2013 Annual report to the nation on Name MM, Gene L, Pairs B, Temp A. 2015 11. Holford TR. 1991 Understanding the effects
the status of cancer, 1975-2009, featuring the Trends in HPV cervical and seroprevalence and of age, period, and cohort on incidence and
burden and trends in human papillomavirus associations between oral and genital infection and mortality rates. Annu. Rev. Public Health 12,
(HPV)-associated cancers and HPV vaccination serum antibodies in NHANES 2003-2012. BMC 425-457. (doi:10.1146/annurev.pu.12.050191.
coverage levels. J. Nat! Cancer Inst. 105, 175-201. Infect. Dis. 15, 575. (doi:10.1186/s12879-015- 002233)
(doi:10.1093/jnci/djs491) 1314-0) 12. Clayton D, Schifflers E. 1987 Models for temporal

3. Brouwer AF, Eisenberg MC, Meza R. 2018 Case 7. Desai S et al. 2011 Prevalence of human variation in cancer rates. Il: Age-period-cohort
studies of gastric, lung, and oral cancer connect papillomavirus antibodies in males and females in models. Stat. Med. 6, 469-481. (doi:10.1002/sim.
etiologic agent prevalence to cancer incidence. England. Sex. Transm. Dis. 38, 622-629. (doi:10. 4780060406)